¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2019 °¡Å縯Ç÷¾×º´¿ø ½ÉÆ÷Áö¾ö ¡°For a Better Understanding of State-of-the art Concepts in Hematologic Diseases ¡± : 2019-06-01

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
2019 °¡Å縯Ç÷¾×º´¿ø ½ÉÆ÷Áö¾ö ¡°For a Better Understanding of State-of-the art Concepts in Hematologic Diseases ¡±  : 2019-06-01
±³À°ÀÏÀÚ : 2019-06-01
±³À°Àå¼Ò : °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ  
±³À°ÁÖÁ¦ : 2019 °¡Å縯Ç÷¾×º´¿ø ½ÉÆ÷Áö¾ö ¡°For a Better Understanding of State-of-the art Concepts in Hematologic Diseases ¡±  
ÁÖÃÖ±â°ü : °¡Å縯´ëÇб³¼­¿ï¼º¸ðº´¿ø
´ã´çÀÚ : ±èµµÈ­
¿¬¶ôó : 02-2258-3005  
À̸ÞÀÏ : hh@cmcnu.or.kr      
±³À°Á¾·ù : ³»°ú      
Âü¼®¿¹»óÀοø : 150¸í
Èñ¸ÁÆòÁ¡ : 5Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 5 ½Ã°£ 0ºÐ  
¼¼ºÎ¼ö°­·á : 50,000¿ø      
ºñ°í »çÀüµî·Ï : Àü¹®ÀÇ-40,000¿ø / Àü°øÀÇ °£È£»ç-20,000¿ø ´çÀϵî·Ï : Àü¹®ÀÇ-50,000¿ø / Àü°øÀÇ °£È£»ç-30,000¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 06-01 °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 09:30~10:20 Registration  () 
±âŸ 06-01 °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 10:20~10:30 Opening remarks  ±èµ¿¿í(°¡Å縯´ëÇб³) 
±³À°½Ã°£ 06-01 °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 10:30~11:00 Minimal residual disease in acute myeloid leukemia and myelodysplastic syndrome  Á¶º´½Ä(°¡Å縯´ëÇб³) 
±³À°½Ã°£ 06-01 °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 11:00~11:30 Biology and Current management for Primary myelofibrosis  ¾ö±â¼º(°¡Å縯´ëÇб³) 
±³À°½Ã°£ 06-01 °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 11:30~12:00 Recent updates in management of Plasma cell myeloma  ¾öÇö¼®(±¹¸³¾Ï¼¾ÅÍ) 
½Ä»ç 06-01 °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 12:00~13:00 ½Ä»ç  () 
±³À°½Ã°£ 06-01 °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 13:00~13:40 Strategies to overcome chemotherapy resistance by controlling tumor microenvironment  ÀÌÈ£¿µ(¼­¿ï´ëÇб³) 
±³À°½Ã°£ 06-01 °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 13:40~14:20 Translational hematology research for aging and cell therapy using non-human primate hematopoietic stem cells  À¯°æ·Ï(°¡Å縯´ëÇб³) 
±³À°½Ã°£ 06-01 °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 14:20~15:00 Cell fate determinants in leukemic progression  ±ÇÇõ¿µ(¼øõÇâ´ëÇб³) 
È޽Ġ06-01 °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 15:00~15:15 Coffee break  () 
±³À°½Ã°£ 06-01 °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 15:15~15:45 Basic Immunology: Harnessing T cells for adoptive cell therapy  ¹ÚÀ±(Çѱ¹°úÇбâ¼ú¿ø) 
±³À°½Ã°£ 06-01 °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 15:45~16:15 Future treatment options using CAR-T cell: From Clinician¡¯s Perspective  ÀÌÀç¿í(°¡Å縯´ëÇб³) 
±³À°½Ã°£ 06-01 °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 16:15~16:45 Practical consideration on manufacturing and commercialization of CAR-T and beyond: From an Industrial Perspective  ±è¼¼¿ø(SL-BIGEN) 
±âŸ 06-01 °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 16:45~17:00 Closing remarks  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2019 °¡Å縯Ç÷¾×º´¿ø ½ÉÆ÷Áö¾ö ¡°For a Better Understanding of State-of-the art Concepts in Hematologic Diseases ¡± : 2019-06-01""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2019 (Á÷¼±Á¦)´ëÇÑ»êºÎÀΰúÀÇ»çȸ Àü±¹¼øȸ¼¼¹Ì³ª : 2019-06-01
´ÙÀ½±Û Ãæ³²´ëÇб³º´¿ø 2019³âµµ ´ëÀü±¤¿ª½ÃÁß±¸,¼­±¸ÀÇ»çȸ Çмú´ëȸ : 2019-06-01
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20435 ´ë±¸ 2024³â ´ëÇÑ°í°üÀýÇÐȸ ±¹Á¦Çмú´ëȸ(ICKHS 2024) (2ÀÏÂ÷) : 2024-05-10 0 74 2024-04-16
20434 ¼­¿ï ´ëÇÑÃÊÀ½ÆÄÀÇÇÐȸ AFSUMB 2024_ Day2 : 2024-05-10 0 53 2024-04-16
20433 ´ë±¸ 2024³â ´ëÇÑ°í°üÀýÇÐȸ ±¹Á¦Çмú´ëȸ(ICKHS 2024) (1ÀÏÂ÷) : 2024-05-09 0 67 2024-04-16
20432 ¼­¿ï ´ëÇÑÃÊÀ½ÆÄÀÇÇÐȸ AFSUMB 2024_Day1 : 2024-05-09 0 58 2024-04-16
20431 ÀüºÏ ´ëÇѽŰæÁ¤½ÅÀÇÇÐȸ ÀüºÏÁöºÎ 5¿ù ÇмúÁý´ãȸ : 2024-05-07 0 44 2024-04-16
20430 Ãæ³² ¼øõÇâ´ëÇб³Ãµ¾Èº´¿ø ½Å»ý¾Æ ¼Ò»ý¼ú ¿¬¼ö°­Á : 2024-05-03 0 57 2024-04-16
20429 ¼­¿ï °­³²¼¼ºê¶õ½ºº´¿ø (¿Â¶óÀÎ) ¼Ò¾Æû¼Ò³â°ú Çù·ÂÀÇ»ç Áý´ãȸ : 2024-04-30 0 97 2024-04-16
20428 ¼­¿ï (¿Â¶óÀÎ) ¸¸¼ºÁúȯ Ä¡·á(Chronic Disease Care)¿¬¼ö±³À° : 2024-04-30 0 103 2024-04-16
20427 °æ±â ÀÌõ½ÃÀÇ»çȸ ¿¬¼ö°­Á : 2024-04-29 0 52 2024-04-16
20426 ´ëÀü ´ëÇѽŰæÁ¤½ÅÀÇÇÐȸ 2024³âµµ 4¿ù ´ëÀüÃæ³²ÁöºÎÇÐȸ ¿ù·ÊÁý´ãȸ : 2024-04-29 0 70 2024-04-16
20425 ºÎ»ê ºÎ»ê´ëÇб³º´¿ø ÇǺΰúÇÐÀÇ ÃÖ½ÅÁö°ß : 2024-04-29 0 65 2024-04-16
20424 ¼­¿ï ´ëÇÑ»óºÎÀ§Àå°ü¡¤Ç︮ÄÚ¹ÚÅÍÇÐȸ Á¦ 30Â÷ ÇмúÁý´ãȸ : 2024-04-29 0 59 2024-04-16
20423 °æ±â (¿Â¶óÀÎ) 2024³â 1Â÷ ¼Ò¾Æ¼ö¸é¿¬±¸È¸ Áý´ãȸ : 2024-04-29 0 103 2024-04-16
20422 ¼­¿ï (¿Â¶óÀÎ) 2024³â ´ëÇÑ°¡¿Í»ç³¢º´ÇÐȸ Çмú´ëȸ (Á¦18ȸ °¡¿Í»ç³¢º´ ½ÉÆ÷Áö¿ò) : 2024-04-28 0 65 2024-04-16
20421 ¼­¿ï 2024³âµµ ´ëÇѽŰæ°úÇÐȸ ÅëÁõ ½Ç±â ¿öÅ©¼ó : 2024-04-28 0 66 2024-04-16
11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷